SUMMARY
SARS-CoV2 infection is typically very mild and often asymptomatic in children. A complication is the rare Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19, presenting 4-6 weeks after infection as high fever and organ dysfunction and strongly elevated markers of inflammation. The pathogenesis is unclear but has overlapping features with Kawasaki disease suggestive of vasculitis and a likely autoimmune etiology. We apply systems-level analyses of blood immune cells, cytokines and autoantibodies in healthy children, children with Kawasaki disease enrolled prior to COVID-19, children infected with SARS-CoV2 and children presenting with MIS-C. We find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19, is more similar to Kawasaki disease, but also differ from this with respect to T-cell subsets, IL-17A and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests endoglin, an endothelial glycoprotein as one of several candidate targets of autoantibodies in MIS-C.
HIGHLIGHTS Hyperinflammation in MIS-C differs from that of acute COVID-19
T-cell subsets discriminate Kawasaki disease patients from MIS-C
IL-17A drives Kawasaki, but not MIS-C hyperinflammation.
Autoantibodies to Endoglin are elevated in MIS-C and a subset of Kawasaki patients
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was made possible by a grant from Knut and Alice Wallenberg Foundation (KAW) to SciLifeLab as well as donations from Bure Equity AB and Jonas and Christina af Jochnick Foundation to Karolinska Institutet and P.B. The authors are also grateful for support from Childrens Hospital Bambino Gesu ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The OPBG Ethics Committees approved both studies and informed consent was obtained from parents or guardians of all patients. Autoantibody analyses in APS-1 patients were approved by Ethical board of Stockholm (Permit: 2016/2553-31/2).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data is available for download: https://ki.app.box.com/s/j3hgvdmkhvhv40gph8snixjgxcz0zpuj and scripts to reproduce the analyses are available through GitHub: https://github.com/Brodinlab/MIS-C_manuscript
